Oxaliplatin
Pediatric Hepatocellular Carcinoma
Explore 10 assets in Pediatric Hepatocellular Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03533582CT.gov Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | — | Active Not Recruiting | — | — | — |
NCT02042443CT.gov Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pediatric Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Children's Oncology Group | P3 | B · 62 |
| Fluorouracilum | Children's Oncology Group | P3 | BB |
| Sorafenib | Children's Oncology Group | P3 | BB |
| Carboplatin | Children's Oncology Group | P3 | B |
| Etoposide | Children's Oncology Group | P3 | B |
| Adriamycin | Children's Oncology Group | P3 | B |
| Irinotecan | Children's Oncology Group | P3 | B |
| Vincristine Sulfate | Children's Oncology Group | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Children's Oncology Group | P3 | B |
+3 more in the Pediatric Hepatocellular Carcinoma cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Pediatric Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-pediatric-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →